新的CLL药品的保险延误迫使病人接受更老、更危险的治疗,结果和费用恶化。 Insurance delays for new CLL drugs push patients to older, riskier treatments, worsening outcomes and costs.

尽管临床准则有利于新BTK抑制剂,但新BTK抑制剂的保险延迟,迫使病人使用较老、较不安全的药物,结果更差,成本更高。 Delays in insurance coverage for newer BTK inhibitors in CLL, despite clinical guidelines favoring them, are forcing patients to use older, less safe drugs, leading to worse outcomes and higher costs. 付款人往往根据成本限制获得治疗的机会,造成治疗准则与补偿之间的差距。 Payers often restrict access based on cost, creating a gap between treatment guidelines and reimbursement. 现实世界证据正在成为更新覆盖面政策的工具,但数据使用不一致和即将进行的《降低通货膨胀法》价格谈判可能会进一步干扰获取服务。 Real-world evidence is emerging as a tool to update coverage policies, but inconsistent data use and upcoming Inflation Reduction Act price negotiations may further disrupt access. 专家们敦促支付者、提供者和监管者之间加强合作,使覆盖范围与现有医疗证据保持一致,并确保患者在不损害创新的情况下及时获得有效治疗。 Experts urge better collaboration among payers, providers, and regulators to align coverage with current medical evidence and ensure patients receive timely, effective treatments without harming innovation.